multiple sclerosis/headache

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1857/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/051482 filed on 24 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1838/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050917 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

PRIORITY TO RELATED APPLICATIONS This application claims the benefit of European Application No. 05101324.1, filed Feb. 22, 2005, which is hereby incorporated by reference in its entirety. BACKGROUND OF THE INVENTION Substance P is a naturally occurring undecapeptide belonging to the tachykinin

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1834/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050909 filed on 3 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

The present invention relates to triazine compounds and cyclic diazo analogs thereof having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. U.S. Pat. No. 4,649,139 discloses compounds of the formula

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Application No. PCT/GB2009/050033, filed on Jan. 16, 2009, which claims the priority date of United Kingdom Application No. 0800741.1, filed on Jan. 16, 2008 the contents of both being hereby incorporated

FIELD OF THE INVENTION The present invention is directed to a series of substituted triazole compounds. In particular, this invention is directed to substituted triazoles that are sodium channel blockers useful for the treatment and prevention of chronic and neuropathic pain. The compounds of the

FIELD OF INVENTION The invention relates to a compound of formula ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen and fluoro. Compounds of formula 1, and pharmaceutically acceptable acid addition salts thereof, have been shown to mediate the Neurokinin 1 (NK-1, substance

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a National Stage Application under 35 U.S.C. .sctn.371 of International Application No. PCT/US2010/002360, filed Aug. 27, 2010, which claims priority under 35 U.S.C. .sctn.119(e) to U.S. Provisional Application Nos. 61/275,506, filed Aug.

FIELD OF THE INVENTION The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB.sub.2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions